Kelly CRISPR & Gene Editing Technology ETF Rating $7.38 0.00 (0.00%) As of 01/17/2025 Add Compare Share Share Ratings Stock AnalysisChartOptions ChainRatingsTrends Kelly CRISPR & Gene Editing Technology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XDNA Aggregate RatingModerate Buy 2.73Holdings in XDNA have an aggregate rating of Moderate Buy based on 307 analyst ratings issued in the past year covering 21 companies (94.6% of the portfolio).XDNA Aggregate Price Target$7.38High Prediction$7.38Average Prediction$7.38Low Prediction$7.38Holdings in XDNA have an aggregate price target of $7.38 and a range of $7.38 to $7.38 covering 21 companies (94.6% of the portfolio).XDNA Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy11 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Kelly CRISPR & Gene Editing Technology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 21 XDNA Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings11.05%NTLAIntellia Therapeutics$9.94+4.6%4.6594 of 5 stars2.72$51.06 413.7%1810.70%TMOThermo Fisher Scientific$572.85+2.4%4.9808 of 5 stars2.86$648.95 13.3%22Positive News9.57%BEAMBeam Therapeutics$24.53+4.7%3.5218 of 5 stars2.92$47.67 94.3%128.64%CRSPCRISPR Therapeutics$41.51+2.4%2.5178 of 5 stars2.47$78.38 88.8%19Short Interest ↑Gap Up6.78%CRBUCaribou Biosciences$1.52-0.7%2.6618 of 5 stars3.00$10.33 579.8%55.63%VERVVerve Therapeutics$6.57+7.0%2.763 of 5 stars3.00$25.75 291.9%45.16%SGMOSangamo Therapeutics$1.13+3.7%2.8391 of 5 stars2.67$5.50 386.7%6Gap Down4.73%PRMEPrime Medicine$2.91+0.7%3.73 of 5 stars3.10$13.13 351.0%104.37%ABBVAbbVie$172.41+0.5%4.9964 of 5 stars2.88$205.50 19.2%24Short Interest ↓Positive News4.13%EDITEditas Medicine$1.21-0.8%4.5322 of 5 stars2.07$7.00 478.5%14Short Interest ↑4.10%ALLOAllogene Therapeutics$1.84+1.1%2.5999 of 5 stars2.90$9.73 429.0%103.32%PSTXPoseida Therapeutics$9.503.2583 of 5 stars2.00$9.50 0.0%52.96%DTILPrecision BioSciences$4.56-8.1%4.3582 of 5 stars3.00$37.67 726.0%32.87%TSVT2seventy bio$2.45-6.1%2.4215 of 5 stars2.56$9.00 267.3%9Analyst ForecastNews CoverageGap Up2.40%AAgilent Technologies$152.61+3.6%4.2518 of 5 stars2.43$143.62 -5.9%14Positive News2.10%BMYBristol-Myers Squibb$57.01+1.3%4.9175 of 5 stars2.29$56.27 -1.3%21Positive News2.00%ILMNIllumina$141.31+3.4%4.5149 of 5 stars2.70$165.63 17.2%201.53%VRTXVertex Pharmaceuticals$427.89+1.4%4.3076 of 5 stars2.52$490.38 14.6%31Positive News1.29%REGNRegeneron Pharmaceuticals$687.80+0.9%4.6151 of 5 stars2.65$1,015.38 47.6%230.69%QGENQiagen$47.54+3.4%3.5988 of 5 stars2.56$51.50 8.3%9Gap Up0.57%BIIBBiogen$140.98+0.3%4.7301 of 5 stars2.43$230.00 63.1%28 This page (NASDAQ:XDNA) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Kelly CRISPR & Gene Editing Technology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
